In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

The vaccine maker is expanding beyond its COVID-focused offerings.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

The technical backdrop, however, points to caution. Seeking Alpha's momentum page flags Moderna as overbought on its relative strength index, with RSI levels indicating the stock has sprinted ahead of ...

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its previously projected $1.6  billion to $2  billion forecast but well ‍below ...

CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it has closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management ...

CHONGQING, CHINA - APRIL 26: In this photo illustration, the logo of Moderna, Inc. is displayed on a smartphone screen, with the company's branding visible in the background, on April 26, 2025, in ...

Moderna stock has dropped along with demand for a product that once drove tremendous growth: the coronavirus vaccine. Investors have remained focused on those declines -- and haven’t yet recognized ...

Moderna's post-pandemic vaccine demand is weak, with mRESVIA unlikely to gain significant RSV market share due to commoditization and entrenched competitors. Financials remain strained: high costs, ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...